SESN Sesen Bio Inc.

1.4
-0.04  -3%
Previous Close 1.44
Open 1.43
Price To Book 2.15
Market Cap 108438652
Shares 77,456,180
Volume 530,271
Short Ratio
Av. Daily Volume 1,022,360

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 181219419
  2. 8-K - Current report 181217402
  3. 8-K - Current report 181184042
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173695
  5. 8-K - Current report 181114159

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 12-month data due mid-2019. 6-month data due December 2018.
Vicinium
Non-muscle invasive bladder cancer (NMIBC)

Latest News

  1. Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer
  2. 3 Health Care Stocks Seeing Heightened Activity After Midterms
  3. Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial Readouts
  4. Implied Volatility Surging for Sesen Bio (SESN) Stock Options
  5. Do Institutions Own Shares In Sesen Bio Inc (NASDAQ:SESN)?
  6. Sesen Bio to Present Three-month VISTA Trial Data at Global Congress on Bladder Cancer 2018
  7. Here's Why Momentum Investors Will Love Sesen Bio (SESN)
  8. Sesen Bio (SESN) Continue to Surge Higher?
  9. 3 Cancer Treatment Stocks that Moved Higher in August
  10. Sesen Bio Reports Second Quarter 2018 Financial Results and Pipeline Updates
  11. Sesen Bio Announces Vicinium Granted Fast Track Designation by FDA for Treatment of Non-Muscle Invasive Bladder Cancer
  12. Sesen Bio Announces CEO and Board Transitions as Company Prepares for 12-Month VISTA Trial Data and Regulatory Submission in 2019
  13. Sesen Bio to Present at the Canaccord Genuity 38th Annual Growth Conference
  14. Free Pre-Market Technical Pulse on Sesen Bio and Three More Biotech Stocks
  15. Stock Performance Review on Sesen Bio and Three Other Biotech
  16. Sesen Bio (SESN) Sees Hammer Chart Pattern: Time to Buy?
  17. Sesen Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock
  18. Sesen Bio Announces Pricing of Public Offering of Common Stock
  19. Sesen Bio Announces Proposed Public Offering of Common Stock
  20. Sesen Bio to Present at the Jefferies 2018 Global Healthcare Conference

SEC Filings

  1. CT ORDER - Confidential treatment order 181219419
  2. 8-K - Current report 181217402
  3. 8-K - Current report 181184042
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173695
  5. 8-K - Current report 181114159
  6. 8-K - Current report 181095899
  7. 8-K - Current report 181026385
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 181014279
  9. 8-K - Current report 181012718
  10. S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments 181009475